| http://www.w3.org/ns/prov#value | - This press release includes forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 that are subject to risks, uncertainties and other factors, including the possibility that the PMDA may not approve sofosbuvir in Japan, and that any marketing approval, if granted, may have significant limitations on their use.
|
